MedPath

Self-administered tDCS for Improving Single- and Dual-task Gait in Patients With PD

Not Applicable
Recruiting
Conditions
Parkinson Disease
Interventions
Device: Transcranial direct current stimulation
Registration Number
NCT06324448
Lead Sponsor
Seoul National University Hospital
Brief Summary

The purpose of this study is to investigate the efficacy and safety of self-administered transcranial direct current stimulation to improve the single- and dual-task gait in patients with Parkinson's disease.

Detailed Description

Parkinson's disease (PD) is a disease caused by dopamine deficiency in the striatum resulting from the loss of dopaminergic neuronal cells in the cerebral substantia. It is a progressive neurodegenerative disease characterized by motor symptoms including gait disturbance and balance instability. In the early stages of Parkinson's disease, dysfunction of the sensorimotor area of the basal ganglia typically occurs, leading to habitual control hurdles. Accordingly, cognitive efforts are required to perform habitual tasks such as walking, and the automaticity of walking is reduced. Dual-task performance involves a complex interplay of motor functions as well as cognitive functions such as attention and executive function. One way to potentially reduce the cost of dual-tasking and the negative effects of motor-cognitive interference is to consider improving the corresponding component, i.e., motor or cognitive function.

Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation method that can be used to change cortical activity. Recently, there has been growing attention on tDCS as an adjunct tool for rehabilitation. Several tDCS studies in patients with PD have reported the positive results of tDCS on motor and cognitive function. Most studies have examined changes before and after a single session of stimulation, with limited research verifying the cumulative and long-term effects of tDCS. Therefore, this study aims to investigate the efficacy and safety of self-administered transcranial direct current stimulation to improve the single- and dual-task gait in patients with PD.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
24
Inclusion Criteria
  • Clinically diagnosed as idiopathic Parkinson's disease by neurologists according to the UK Parkinson's Disease Society Brain Bank criteria
  • modified Hoehn & Yahr stage 2, 2.5, or 3
Exclusion Criteria
  • History of seizure
  • Metallic implants, such as cardiac pacemaker or an artificial cochlea
  • Patients with inflammation, burns, or wounds in the stimulation area
  • Parkinson's disease dementia; cut-off is < 7 of Korean-Montreal Cognitive Assessment for illiterate patients, < 13 for those educated for 0.5-3 years, < 16 for 4-6 years of education, < 19 for 7-9 years of education, and < 20 for 10 or more years of education.
  • Severe dyskinesia or severe on-off phenomenon
  • Plan to adjust medication at the time of screening
  • Other neurological, orthopedic, or cardiovascular co-morbidities significantly affecting gait function
  • Uncontrolled vestibular disease, orthopedic hypotension, or paroxysmal vertigo
  • Pregnant or lactating patients
  • Other comorbidities that make it difficult to participate in this study

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Primary motor cortexTranscranial direct current stimulationThe anodal electrode is positioned in the primary motor cortex (Cz) and the cathodal electrode on the right orbital frontal cortex (Fp2). The current increases to 2.0 mA over a period of 30 seconds, maintains 2.0 mA for 19 minutes, and decreases to 0 mA over 30 seconds.
Left dorsolateral prefrontal cortexTranscranial direct current stimulationThe anodal electrode is positioned in the left dorsolateral prefrontal cortex (F3) and the cathodal electrode on the right orbital frontal cortex (Fp2). The current increases to 2.0 mA over a period of 30 seconds, maintains 2.0 mA for 19 minutes, and decreases to 0 mA over 30 seconds.
Primary Outcome Measures
NameTimeMethod
Timed-up and go test under dual-task condition (sec)Immediate post-intervention
Timed-up and go test (sec)Immediate post-intervention
Secondary Outcome Measures
NameTimeMethod
modified Attention Allocation Index (mAAI) in Timed-up and go testFollow-up (1 month)

modified Attention Allocation Index (mAAI)=motor dual task effect(mDTE)-cognitive dual task effect (cogDTE)

Trail making testFollow-up (1 month)

The trail-making test is a neuropsychological measure that assesses psychomotor speed, attention, sequencing, mental flexibility, and visual scanning.

Stroop testFollow-up (1 month)

The Stroop test evaluates attention, executive function, processing speed, and cognitive flexibility regarding an individual's ability to inhibit the habitual response.

Timed-up and go test (sec)Follow-up (1 month)
Dual-task effect (%) in Timed-up and go testFollow-up (1 month)

Percentage of dual-task effect calculated by the difference between dual-task and single-task performance \[Percentage of dual-task interference=(Dual-task performance - Single-task performance)/Single-task performance\]

Single-leg stance testFollow-up (1 month)
New freezing of gait questionnaire (NFoGQ)Follow-up (1 month)

NFoGQ consists of 6 items. Total score ranges from 0 to 24. the higher scores, the more negative results.

Geriatric depression scale (GDS)-short formFollow-up (1 month)

The GDS Short Form contains 15 items. The higher the score, the more negative the result.

Gait parametersFollow-up (1 month)

Symmetric temporospatial parameters, Normal cadence, Decreased \& intolerable walking velocity, Normal step length differential, Normal step length on both sides, Normal stride length on both sides, Normal swing phase \& stance phase on both sides, Normal single support time \& double support time on both sides, Slightly widened base of support on both sides, Increased foot angle on right side

Timed-up and go test under dual-task condition (sec)Follow-up (1 month)

Trial Locations

Locations (1)

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath